ClinicalTrials.gg
Active, not recruitingNCT06171217REACHUpdated Apr 21, 2026

Realizing Effectiveness Across Continents With Hydroxyurea

A Phase 2 interventional study of Hydroxyurea and Hydroxyurea in Sickle Cell Disease and Children, sponsored by Children's Hospital Medical Center, Cincinnati. Active, not recruiting at 4 sites in 4 countries. Open to participants aged 3 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
811
Allocation
Non-randomized
Ages
3 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing hydroxyurea in Anemia, Sickle Cell — 8 open to participants now, 14 under way, 1 of them phase 3. Hydroxyurea · Anemia, Sickle Cell.

Enrollment
Largest of 57
811 · median 50
Started
2023
with 2 others
Phase 2
20 of 59
3 open now
Primary completion
2027-10
later than 8 of 13 live
Registered
55th of 59
by date
Lead sponsor
9 of 59
Children's Hospital Medical Center, Cincinnati

Among the 59 studies testing hydroxyurea in Anemia, Sickle Cell, this one has the largest enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2023, is one of 20 in phase 2, reaches primary completion later than 8 of the 13 other live ones, and was the 55th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

8 of the 59 studies testing hydroxyurea in Anemia, Sickle Cell are open now, in 6 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About hydroxyurea

Hydroxyurea: first FDA approval 1967 (DROXIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 3 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing hydroxyurea in Anemia, Sickle Cell, or all of them as a file.
02

Study summary

REACH is a prospective, phase I/II open-label dose escalation trial of hydroxyurea for children with confirmed SCA between 3 and 10 years of age. The short-term goal is to obtain critical pilot data regarding the feasibility, safety, and benefit of hydroxyurea for children with SCA in multiple distinct research settings in Africa. Based on that information, the longer-term goal is to make hydroxyurea more widely available for children with SCA in Africa, particularly those identified with SCA through expanded newborn screening programs.

Read the detailed description

REACH is a prospective, phase I/II open-label dose escalation trial of hydroxyurea for children with confirmed SCA between 3 and 10 years of age. The short-term goal is to obtain critical pilot data regarding the feasibility, safety, and benefit of hydroxyurea for children with SCA in multiple distinct research settings in Africa. Based on that information, the longer-term goal is to make hydroxyurea more widely available for children with SCA in Africa, particularly those identified with SCA through expanded newborn screening programs. In the REACH prospective trial, the Original Cohort will receive long-term treatment while for the New Cohort, treatment will continue at least 4 years using PK-guided dosing after an initial 3-month screening period.

03

Conditions studied

  • Sickle Cell Disease
  • Children

Browse trials for

04

Who can participate

Ages eligible
3 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pediatric patients with documented sickle cell anemia (typically HbSS supported by electrophoresis, complete blood count, and peripheral blood smear)
  2. In the Original Cohort, age range of 1.00-9.99 years, inclusive, at the time of enrollment (now age 5.5 - 17.5 years); age range 3.0-10.0 years for the New Cohort
  3. Weight at least 10.0 kg at the time of enrollment
  4. Parent or guardian willing and able to provide written , with child's verbal assent as per local IRB/Ethics Board requirements
  5. Willingness to comply with all study-related treatments, evaluations, and follow-up

Exclusion criteria

Exclusion Criteria

  1. Known medical condition making participation ill-advised (e.g., acute or chronic infectious disease, , or )
  2. Acute or chronic severe malnutrition determined by impaired growth parameters as defined by WHO (weight for length/height or height for age >3 z-scores below the median WHO growth standards.
  3. Pre-existing severe hematological toxicity (temporary exclusions)

    1. Anemia: \<4.0 g/dL
    2. Anemia: Hb \<6.0 g/dL with ARC \<100 x 109/L
    3. Reticulocytopenia: ARC \<80 x 109/L with Hb \<7.0 g/dL
    4. Thrombocytopenia: \<80 x 109/L
    5. Neutropenia: ANC \<1.0 x 109/L
  4. Blood transfusion within 60 days before enrollment (temporary exclusion)
  5. In the Original Cohort, hydroxyurea use within 6 months before enrollment (temporary exclusion). In the New Cohort, the children should be hydroxyurea naïve, without any prior treatment exposure.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
811 participants (actual)

Study arms

  • Experimental
    Original Cohort

    The original REACH cohort continuing study treatment per the protocol schedule of evaluations.

    Drug: Hydroxyurea

  • Experimental
    New Cohort

    Newly enrolled REACH participants consent, 3 months screening, and treatment per the protocol schedule of evaluations

    Drug: Hydroxyurea

Interventions

  • Hydroxyurea, approximately 20-30 mg/kg/day, with modifications for toxicity or for mild marrow suppression

  • Hydroxyurea 15-35 mg/kg/day based on PK-guided dosing, with modifications for toxicity for mild marrow suppression

06

What researchers measure

Primary outcomes

  1. Efficacy of long-term Hydroxyurea treatment at MTD

    The efficacy of hydroxyurea will be primarily assessed through fetal hemoglobin (HbF), comparing treatment with baseline values.

    Time frame: Assessed every 6 ± 1 months up to 204 months

Secondary outcomes

  1. Reduction of malaria incidents while on hydroxyurea at MTD.

    Clinical malaria infections to identify associations of risk or protection comparing treated and untreated incidents.

    Time frame: Assessed every 4 ± 1 weeks, then every 3 ± 1months up to 204 months

  2. Success of PK-guided dosing of hydroxyurea

    Fetal Hemoglobin changes from hydroxyurea at MTD

    Time frame: Assessed every 6 ± 1 months up to 204 months

07

Study locations

4 sites
  • Hospital Pediátrico David Bernardino
    Luanda, Angola
  • Centre Hospitalier Monkole
    Kinshasa, Democratic Republic of the Congo
  • KEMRI/Wellcome Trust Research
    Kilifi, Kenya
  • Mbale Regional Hospital
    Mbale, Uganda
08

References and documents

Publications

  • Backeljauw P, Tomlinson G, Smart LR, Tshilolo L, Williams TN, Santos B, Olupot-Olupot P, Stuber S, Lane A, Latham T, Ware RE. Growth and puberty in African children with sickle cell anemia treated with hydroxyurea. Blood Adv. 2026 Jul 14;10(13):4483-4494. doi: 10.1182/bloodadvances.2025019511. PubMed 41954645 ↗

Individual participant data

Plan to share: Yes — Investigators whose proposed use of the data has been approved by a review committee identified for this purpose, will be provided individual participant data that underlie the results reported from this study, after de-identification and publication. The data can be obtained via email to Dr. Ware as the corresponding author.

Supporting information: Study protocol

Time frame: Nine months following publication ending 36 months following publication.

Access criteria: For individual participant data meta-analysis after approval of a proposal and with a signed data access agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Oct 2027, 47 months after the start.

Of 59 non-industry phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 117. This study's planned 47 months is below that.

Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2023
First posted
Dec 14, 2023
StartActual
Oct 27, 2023
Primary completionEst.
Oct 4, 2027
CompletionEst.
Oct 4, 2033
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06171217
Responsible party
Sponsor
First posted
Dec 14, 2023
Start date
Oct 27, 2023
Primary completion
Oct 4, 2027 (estimated)
Completion
Oct 4, 2033 (estimated)
Last update
Apr 21, 2026

Study contacts

Russell Ware, MD, PhD
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydroxyurea

Start the discussion